Quince Therapeutics: A Company Without A Suitable Plan (NASDAQ:QNCX)



Quince Therapeutics (NASDAQ:QNCX) was previously Cortexyme, a biotech firm that was advancing a therapy for Alzheimer’s illness. Their first scientific stage asset, a small molecule (COR-388) that targets P. gingivalis’ (PG) position in degenerative illness development, failed to fulfill the pre-specified endpoints in a placebo managed section